These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29133777)

  • 1. Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.
    Zhang G; Zhang Y; Wu J; Chen Y; Ma Z
    Am J Case Rep; 2017 Nov; 18():1204-1208. PubMed ID: 29133777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children.
    Kobayashi K; Mitsui K; Ichikawa H; Nakabayashi K; Matsuoka M; Kojima Y; Takahashi H; Iijima K; Ootsubo K; Oboki K; Okita H; Yasuda K; Sakamoto H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Ohara A
    Br J Haematol; 2014 Jun; 165(6):836-41. PubMed ID: 24628626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation.
    Kobayashi K; Miyagawa N; Mitsui K; Matsuoka M; Kojima Y; Takahashi H; Ootsubo K; Nagai J; Ueno H; Ishibashi T; Sultana S; Okada Y; Akimoto S; Okita H; Matsumoto K; Goto H; Kiyokawa N; Ohara A
    Pediatr Blood Cancer; 2015 Jun; 62(6):1058-60. PubMed ID: 25400122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.
    Ishibashi T; Yaguchi A; Terada K; Ueno-Yokohata H; Tomita O; Iijima K; Kobayashi K; Okita H; Fujimura J; Ohki K; Shimizu T; Kiyokawa N
    Exp Hematol; 2016 Mar; 44(3):177-88.e5. PubMed ID: 26703895
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Zhang Y; Gao Y; Zhang H; Zhang J; He F; Hnízda A; Qian M; Liu X; Gocho Y; Pui CH; Cheng T; Wang Q; Yang JJ; Zhu X; Liu X
    Blood; 2018 May; 131(20):2256-2261. PubMed ID: 29434033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
    Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
    Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
    Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
    Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain.
    van Outersterp I; Tasian SK; Reichert CEJ; Boeree A; de Groot-Kruseman HA; Escherich G; Boer JM; den Boer ML
    Blood; 2024 May; 143(21):2178-2189. PubMed ID: 38394665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research Progress on Pathogenic Genes of Ph-like Acute Lymphoblastic Leukemia--Review].
    Li ZZ; Wang YJ; Feng JK; Tan JB; Zhao RB; Yang TH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):695-699. PubMed ID: 32319419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL.
    Xu GF; Zeng Z; Zhang ZB; Zhang XM; Wang M; Xiao Q; Li J; Xie XQ; He S; Fu HH; Liu Y; Yang ZL; Chen Y; Shi J; Wang B; Qiu HY; Zhou Q; Liu Y; Chen SN
    J Cell Mol Med; 2024 Feb; 28(3):e18114. PubMed ID: 38323741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with
    Fazio F; Barberi W; Cazzaniga G; Fazio G; Messina M; Della Starza I; De Propris MS; Mancini F; Mohamed S; Del Giudice I; Chiaretti S; Moleti ML; Guarini A; Foà R; Testi AM
    Leuk Lymphoma; 2020 Feb; 61(2):469-472. PubMed ID: 31558067
    [No Abstract]   [Full Text] [Related]  

  • 12. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
    Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
    Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
    Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
    Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.
    Welsh SJ; Churchman ML; Togni M; Mullighan CG; Hagman J
    Leukemia; 2018 Jan; 32(1):38-48. PubMed ID: 28555080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel subclonal rearrangement of the STRN3::PDGFRB gene in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects.
    Wang Z; Liu T; Liu W; Gao X; Wan L; Qiu S; Song Y; Gu R; Tian Z; Wang M; Wang J; Mi Y; Wei S
    Cancer Gene Ther; 2023 Nov; 30(11):1471-1484. PubMed ID: 37550570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
    Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
    N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.
    Weston BW; Hayden MA; Roberts KG; Bowyer S; Hsu J; Fedoriw G; Rao KW; Mullighan CG
    J Clin Oncol; 2013 Sep; 31(25):e413-6. PubMed ID: 23835704
    [No Abstract]   [Full Text] [Related]  

  • 18. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review.
    Sakurai Y; Sarashina T; Toriumi N; Hatakeyama N; Kanayama T; Imamura T; Osumi T; Ohki K; Kiyokawa N; Azuma H
    J Pediatr Hematol Oncol; 2021 Jan; 43(1):e105-e108. PubMed ID: 32068648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
    Hunger SP
    Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.